Back to mobile site

Form SCHEDULE 13G Fulcrum Therapeutics, Filed by: EcoR1 Capital, LLC

June 25, 2026 5:51 PM EDT





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
   Rule 13d-1(b)
   Rule 13d-1(c)
   Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person:  Percentage calculated based on 66,633,321 shares of Common Stock outstanding on April 20, 2026, as reported in the Form 10-Q filed by the Issuer for the quarterly period ended March 31, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  Percentage calculated based on 66,633,321 shares of Common Stock outstanding on April 20, 2026, as reported in the Form 10-Q filed by the Issuer for the quarterly period ended March 31, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  Percentage calculated based on 66,633,321 shares of Common Stock outstanding on April 20, 2026, as reported in the Form 10-Q filed by the Issuer for the quarterly period ended March 31, 2026.


SCHEDULE 13G



 
EcoR1 Capital, LLC
 
Signature:/s/ Oleg Nodelman
Name/Title:Manager
Date:06/25/2026
 
Oleg Nodelman
 
Signature:/s/ Oleg Nodelman
Name/Title:Reporting person
Date:06/25/2026
 
EcoR1 Capital Fund Qualified, L.P.
 
Signature:/s/ Oleg Nodelman
Name/Title:Manager of the General Partner, EcoR1 Capital, LLC
Date:06/25/2026
Exhibit Information

EXHIBIT 99 - AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G

ATTACHMENTS / EXHIBITS

ex991.htm



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings

Related Entities

13G